BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

883 related articles for article (PubMed ID: 27992414)

  • 21. Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted Therapy.
    Gill H; Leung AY; Kwong YL
    Int J Mol Sci; 2016 Mar; 17(4):440. PubMed ID: 27023522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
    Chiereghin C; Travaglino E; Zampini M; Saba E; Saitta C; Riva E; Bersanelli M; Della Porta MG
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Sequential acquisition of mutations in myelodysplastic syndromes].
    Makishima H
    Rinsho Ketsueki; 2017; 58(10):1828-1837. PubMed ID: 28978821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia.
    Chen X; Othus M; Wood BL; Walter RB; Becker PS; Percival ME; Abkowitz JL; Appelbaum FR; Estey EH
    Leuk Lymphoma; 2021 May; 62(5):1226-1233. PubMed ID: 33345655
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening for myeloid mutations in patients with myelodysplastic syndromes and AML with myelodysplasia-related changes.
    Bezerra MF; Larrazábal BR; Lima AS; Mello MR; Pimentel RF; Weinhäuser I; Costa FF; Fertrin KY; Araújo AS; Machado CG; Bezerra MA; Lucena-Araujo AR
    Hematol Transfus Cell Ther; 2022; 44(3):328-331. PubMed ID: 33454286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression.
    Menssen AJ; Khanna A; Miller CA; Nonavinkere Srivatsan S; Chang GS; Shao J; Robinson J; O'Laughlin M; Fronick CC; Fulton RS; Brendel K; Heath SE; Saba R; Welch JS; Spencer DH; Payton JE; Westervelt P; DiPersio JF; Link DC; Schuelke MJ; Jacoby MA; Duncavage EJ; Ley TJ; Walter MJ
    Blood Cancer Discov; 2022 Jul; 3(4):330-345. PubMed ID: 35709710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2
    Todisco G; Creignou M; Gallì A; Guglielmelli P; Rumi E; Roncador M; Rizzo E; Nannya Y; Pietra D; Elena C; Bono E; Molteni E; Rosti V; Catricalá S; Sarchi M; Dimitriou M; Ungerstedt J; Vannucchi AM; Hellström-Lindberg E; Ogawa S; Cazzola M; Malcovati L
    Leukemia; 2021 Aug; 35(8):2371-2381. PubMed ID: 33349666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.
    Thol F; Kade S; Schlarmann C; Löffeld P; Morgan M; Krauter J; Wlodarski MW; Kölking B; Wichmann M; Görlich K; Göhring G; Bug G; Ottmann O; Niemeyer CM; Hofmann WK; Schlegelberger B; Ganser A; Heuser M
    Blood; 2012 Apr; 119(15):3578-84. PubMed ID: 22389253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Molecular features and prognostic value of RAS mutations in patients with myelodysplastic syndromes].
    Huang HJ; Li B; Qin TJ; Xu ZF; Hu NB; Pan LJ; Qu SQ; Liu D; Zhang YD; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2020 Sep; 41(9):723-730. PubMed ID: 33113603
    [No Abstract]   [Full Text] [Related]  

  • 30. Tumor genetic alterations and features of the immune microenvironment drive myelodysplastic syndrome escape and progression.
    Montes P; Bernal M; Campo LN; González-Ramírez AR; Jiménez P; Garrido P; Jurado M; Garrido F; Ruiz-Cabello F; Hernández F
    Cancer Immunol Immunother; 2019 Dec; 68(12):2015-2027. PubMed ID: 31705171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.
    Machado-Neto JA; Traina F; Lazarini M; Campos Pde M; Pagnano KB; Lorand-Metze I; Costa FF; Saad ST
    Clinics (Sao Paulo); 2011; 66(5):793-9. PubMed ID: 21789382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.
    Shiba N; Yoshida K; Shiraishi Y; Okuno Y; Yamato G; Hara Y; Nagata Y; Chiba K; Tanaka H; Terui K; Kato M; Park MJ; Ohki K; Shimada A; Takita J; Tomizawa D; Kudo K; Arakawa H; Adachi S; Taga T; Tawa A; Ito E; Horibe K; Sanada M; Miyano S; Ogawa S; Hayashi Y
    Br J Haematol; 2016 Nov; 175(3):476-489. PubMed ID: 27470916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The Correlation of Gene Mutation and Clinical Characteristics in Patients with Myelodysplastic Syndrome and Prognostic Analysis].
    Zhang WW; Zhang YL; Ren CC; Wu TK; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):176-183. PubMed ID: 38387918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic and epigenetic pathways in myelodysplastic syndromes: A brief overview.
    Jhanwar SC
    Adv Biol Regul; 2015 May; 58():28-37. PubMed ID: 25499150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clonal evolution in inherited marrow failure syndromes predicts disease progression.
    Schratz KE
    Hematology Am Soc Hematol Educ Program; 2023 Dec; 2023(1):125-134. PubMed ID: 38066914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes.
    Walter MJ; Shen D; Shao J; Ding L; White BS; Kandoth C; Miller CA; Niu B; McLellan MD; Dees ND; Fulton R; Elliot K; Heath S; Grillot M; Westervelt P; Link DC; DiPersio JF; Mardis E; Ley TJ; Wilson RK; Graubert TA
    Leukemia; 2013 Jun; 27(6):1275-82. PubMed ID: 23443460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
    Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC
    Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational landscape of chronic myelomonocytic leukemia in Chinese patients.
    Nie Y; Shao L; Zhang H; He CK; Li H; Zou J; Chen L; Ji H; Tan H; Lin Y; Ru K
    Exp Hematol Oncol; 2022 May; 11(1):32. PubMed ID: 35610628
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of RUNX1 Gene Mutation in Patients with Myelodysplastic Syndrome].
    Cai XH; Chen MY; Chao HY; Jiang NK; Lu XZ; Han WM; Qin W; Jia ZX
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):202-208. PubMed ID: 32027277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.